Estate Planning Dilemma Can Family Cash Out CDs of Father in Hospice Care
UK Student Loans Inquiry Draws Over 52000 Responses Highlighting Massive Scale of Frustration and Upset
Jim Cramers Vote of Confidence on Intuit INTU Preceded a Steep Decline
Micron Technology Shares Eye Best Monthly Performance Since 1987 Analysts Flag Value Opportunity
BMO Capital Reaffirms Outperform Rating on SAP After Sapphire 2026 Conference Price Target Set at 200
Tui Ends Sponsorship of Married at Age After Sexual Misconduct Allegations
TS Q1 2026 Earnings EPS Surpasses Estimates But Stock Slips Amid Uncertain Revenue Outlook
XXII Q1 2026 Earnings Significant EPS Miss Highlights Continued Challenges
LMT Q1 2026 Earnings Earnings Miss Stock Rises Amid Defense Sector Optimism
LLYVK Q4 2025 Earnings EPS Nearly Matches Estimates but Surprise Miss and Flat Revenue Weigh on Sentiment
Hyliion Holdings Corp HYLN Q1 2026 Earnings Narrower Loss Fuels 42 Rally
SXI Q1 2026 Earnings Modest EPS Miss Amidst Solid Operational Performance
CollPlant Biotechnologies CLGN Slides 667 as Selling Pressure Mounts
Rapport Therapeutics RAPP Holds Steady as Minor Decline Tests Key Support Levels
Summit Midstream Corporation SMC Faces Resistance After 36 Decline
New Era Energy Digital Inc NUAI Rallies 4 as Stock Approaches Key Resistance
AgEagle Aerial Systems UAVS Surges 5 as Shares Test Key Resistance at 107
EU Imposes 230M Fine on Temu Over Alleged Illegal Product Sales
AAUC Q1 2026 Earnings EPS Surges 82 Above Estimates Exceeding Expectations
Sotherly Hotels Preferred Stock SOHOB Plunges Over 8 as Support Levels Tested
ATT Q1 2026 Earnings EPS Slightly Beats Estimates Stock Edges Lower
Ainos Inc AIMD Q1 2025 Earnings Continued Adjusted Losses Amid Strategic Pivot
SVRA Q1 2026 Earnings Wider Loss Amid Continued Pipeline Development
Willis Lease Finance Corporation WLFC Q1 2026 Earnings Substantial EPS Surprise Highlights Strong Operating Performance
ENSG Q1 2026 Earnings Slight EPS Miss Amidst Steady Operations
DMAC Q1 2026 Earnings WiderthanExpected Loss as Clinical Development Costs Persist
ABUS Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Pipeline